Repotrectinib in patients (pts) from Asia and China with ROS1 fusion- positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
S. Lu,X. Hu,S-W. Kim,K. Goto,N. Yang,R. A. Soo,J. Fang,W. Yao,K. H. Lee,D. W-T. Lim,T. Kato,M. Tamiya,J. Wu,Y. Zhang,J. Zhou,F. Ades,J. Hua,P. T. Wang,B. C. Cho
